Find Jobs

Contract opportunities for Engineering professionals in Denmark’s Life Science Sector

The Danish Life Sciences Industry is one of the most prestigious and accomplished in the world. Close collaboration between the public and private sectors, high-tech production and an attractive business environment are some of the factors that have contributed to its success. Over the past few decades, the Life Sciences sector has grown considerably in Denmark and 2020 has seen further investment from major players in the industry.

At present, the market is extremely busy with a number of new greenfield sites and exciting facility upgrades occurring presently. LSC are currently working with multinational Pharma and Biotech clients and have great opportunities for experienced engineers who can help the industry to ramp up and meet project demands during this expansion phase.

If you’re an experienced Engineer with 5+ years’ experience in Biotech we have exciting contracts across the following disciplines:

  • C&Q Engineer
  • Design Manager
  • Mechanical Engineer
  • Piping Designer
  • Process Design Engineer
  • Project Director
  • Project Manager
  • Project Planner

If you’re experienced in the above and ready for a new challenge in Europe, we would love to hear from you.

Click below to submit your CV or get in contact with a member of our resourcing team today to find out more about contracts in Denmark!

Interested in project opportunities in Denmark?

Send us your details and we'll be in touch shortly

DANISH LIFE SCIENCE NEWS 2020

Fujifilm plots $928M infusion at Danish biologics plant to double production capacity

Fujifilm will dole out a whopping $928 million at a former Biogen site in Denmark it acquired in August for $890 million, the Japanese drugmaker said Tuesday. The company’s major capital outlay for its Fujifilm Diosynth Biotechnologies CDMO site will dramatically expand the facility’s bulk drug manufacturing capacity, finish/fill capabilities and packaging output by fall 2023. Click here for the full article >> 

Novo Nordisk moves further into CV diseases with Corvidia acquisition

Danish pharma company Novo Nordisk has entered a definitive agreement to acquire Massachusetts-headquartered Corvidia Therapeutics. The deal involves an upfront payment of $725m, but Corvidia could be eligible to receive around $2.1bn upon the completion of regulatory and sales milestones related to its cardio-renal pipeline. Click here for the full article >>

Contact a member of our team to find out more about opportunities in Denmark

Ruth Holland
Technical Resourcer
E: [email protected]
T: +353 21 4777 329

Martin Taggart Engineering LSC

Martin Taggart
Technical Resourcer
E: [email protected]
T: +353 21 4777 329

Start typing and press Enter to search